Skip to main content
SpringerLink
Log in

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

This study investigates whether the response criteria proposed by the European LeukemiaNet (ELN) to evaluate cytoreductive therapies in essential thrombocythemia (ET) correlate with clinically relevant outcomes in patients receiving anagrelide. We evaluated 154 ET patients treated with anagrelide (upfront in 87) for a median of 2.9 years. Complete response (CR), partial response, and no response were observed in 56, 30.5, and 13.5 % patients, respectively. Only 38 patients (25 %) achieved a sustained CR. Overall, the aggregated time on CR and without CR was 200.1 and 333.6 person-years, respectively. The incidence rate of thrombosis and hemorrhage was independent of the CR status. The only factor associated with shorter survival after anagrelide start was the patient's age, whereas achieving a CR with anagrelide had no predictive value for subsequent survival. In conclusion, CR according to the ELN definition is not associated with any measurable clinical benefit in ET patients treated with anagrelide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473

    Article  PubMed  CAS  Google Scholar 

  2. Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24):4642–4649

    Article  PubMed  Google Scholar 

  3. Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051

    Article  PubMed  CAS  Google Scholar 

  4. Barosi G, Birgegard G, Finazzi G et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113(20):4829–4833

    Article  PubMed  CAS  Google Scholar 

  5. Hernandez-Boluda JC, Alvarez-Larran A, Gomez M et al (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152(1):81–88

    Article  PubMed  Google Scholar 

  6. Alvarez-Larran A, Pereira A, Cervantes F et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363–1369

    Article  PubMed  CAS  Google Scholar 

  7. Carobbio A, Finazzi G, Antonioli E et al (2010) Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood 116(7):1051–1055

    Article  PubMed  CAS  Google Scholar 

  8. Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092–1097

    Article  PubMed  CAS  Google Scholar 

  9. Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33–45

    Article  PubMed  CAS  Google Scholar 

  10. Tang SS, Frojmovic MM (1980) Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3′, 5′-adenosine monophosphate phosphodiesterase. J Lab Clin Med 95(2):241–257

    PubMed  CAS  Google Scholar 

  11. Barosi G, Tefferi A, Barbui T (2012) Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia 26(5):1148–1149

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the members of the Registro Español de Trombocitemia Esencial (RETE) for providing the patients' clinical information, as well as Juncal Sabaté for helping on collecting the database. This work was supported by the grants 09/02324 and 10/01807 from the Fondo de Investigaciones Sanitarias and RETICS RD12/0036/0010, from the Spanish Ministry of Health, and IMPULSA/2010 from the Conselleria de Sanitat, Generalitat Valenciana, Spain.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Hematology and Medical Oncology Department, Hospital Clínico Universitario, Avd. Blasco Ibáñez 17, 46010, Valencia, Spain

    Juan Carlos Hernández-Boluda & Montse Gómez

  2. Hemotherapy and Hemostasis Department, Hospital Clínic, Barcelona, Spain

    Arturo Pereira & Eduardo Arellano-Rodrigo

  3. Hematology Department, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain

    Francisco Cervantes

  4. Hematology Department, Hospital del Mar, Barcelona, Spain

    Alberto Alvarez-Larrán & Carles Besses

  5. Hematology and Medical Oncology Department, Hospital Morales Meseguer, Murcia, Spain

    Francisca Ferrer-Marín

  6. Hematology Department, Hospital La Paz, Madrid, Spain

    Ana Kerguelen

  7. Hematology Department, Hospital Basurto, Bilbao, Spain

    José Antonio Márquez

  8. Hematology Department, Complejo Hospitalario de Navarra, Pamplona, Spain

    María Luisa Antelo

Authors
  1. Juan Carlos Hernández-Boluda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arturo Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francisco Cervantes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Montse Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduardo Arellano-Rodrigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alberto Alvarez-Larrán
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francisca Ferrer-Marín
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ana Kerguelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. José Antonio Márquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. María Luisa Antelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Carles Besses
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)

Corresponding author

Correspondence to Juan Carlos Hernández-Boluda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernández-Boluda, J.C., Pereira, A., Cervantes, F. et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol 92, 771–775 (2013). https://doi.org/10.1007/s00277-013-1683-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1683-7

Keywords

Search

Navigation